Open Accessibility Menu

Clinical Trial Information

A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects with Active Cutaneous Lupus Erythematosus.

Study Details

The goal of this study is to evaluate the efficacy of BIIB059 in reducing disease activity in subjects with active cutaneous lupus erythematosus (CLE). The subject screening period will last up to 4 weeks. This will be followed by a treatment period of 16 weeks, with subjects randomized to 1 of 4 possible arms, all which will receive monthly treatments given in the office. Two groups will receive BIIB059 and two groups will receive the placebo. The following safety follow-up period will consist of 12 weeks of monthly visits.

Primary Sponsor:

Biogen MA, Inc.

Prinicipal Investigator:

Alison Ehrlich, MD, MHS/Dermatology

Contact Phone:

(202) 677-6160
A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects with Active Cutaneous Lupus Erythematosus. mrengifopardo@mfa.gwu.edu

Interested in More Information

  • Please enter your first name.
  • Please enter your last name.
  • This isn't a valid email address.
    Please enter your email address.
  • This isn't a valid phone number.
    Please enter your phone number.
    You entered an invalid number.
  • Please enter your address.
  • Please enter your city.
  • Please enter your state.
  • Please enter your zip code.
  • (All Uppercase. No Spaces)